TB500

Buy TB-500 (Body Pharm) in Australia — Mechanism, Research & Regulatory Guide

Ready to order? Browse Body Pharm TB-500 products now — view all TB-500 listings on JCSG.org.

TB-500 is a synthetic 17-amino-acid fragment of Thymosin-β4 that contains the LKKTET actin-binding motif, sequesters monomeric G-actin, and modulates Akt-pathway signalling to drive angiogenesis and cell migration [18]. As of 2026, it has no ARTG (Australian Register of Therapeutic Goods) registration in Australia [3], sits in Category 2 (withdrawn) on the US FDA 503B Bulks List as of 22 April 2026 [11], and is prohibited in sport under WADA's S0 Non-Approved Substances class on the 2026 Prohibited List [13][14].

This page traces that mechanism end-to-end and maps it against TGA (Therapeutic Goods Administration), FDA (Food and Drug Administration), and EMA (European Medicines Agency) classifications. By the end, you will understand TB-500's molecular action, the evidence gap between fragment and full-length protein, why it is banned in sport, and how it compares to BPC-157 in research protocols.

One caveat upfront: most human efficacy data cited for TB-500 are extrapolated from full-length Thymosin-β4 trials, because no interventional human trials of the TB-500 fragment itself are registered on ClinicalTrials.gov or ANZCTR (Australian New Zealand Clinical Trials Registry) as of 2025 [8][9].

JCSG.org stocks Body Pharm TB-500 for Australian researchers. Order TB-500 on JCSG.org — check the current price in the buy box above.

Key Takeaways

• TB-500 is a synthetic 7-amino-acid fragment of Thymosin-β4, not the full protein; most human data come from full-length Tβ4 studies, not the fragment itself.
• The peptide sequesters monomeric G-actin via the LKKTET motif, enabling cell migration and angiogenesis in animal models and cell culture.
• No registered human trial of TB-500 exists as of 2026; all human efficacy claims are extrapolations from full-length Tβ4 data or preclinical work.
• TB-500 is unapproved for human use in Australia, the US, and the EU; it is prohibited in sport under WADA S0 (Non-Approved Substances).
• Researchers often pair TB-500 with BPC-157 because they act through distinct pathways — actin sequestration versus growth-factor signalling.
• Side-effect profile in humans is unknown; animal studies reported few acute toxicities, but chronic safety and organ-system effects remain uncharacterised.
• Body Pharm TB-500 is available now on JCSG.org — browse the full TB-500 range.

What Is TB-500? A Precise Definition

TB-500 is a synthetic N-acetylated heptapeptide with the sequence Ac-LKKTETQ, corresponding to amino acids 17–23 of the 43-residue Thymosin-β4 (TB4) protein, with a molecular weight of approximately 889 Da [1][3]. It is not full-length TB4. The fragment isolates the LKKTET actin-binding motif and a flanking glutamine, omitting the N- and C-terminal regions that govern TB4's broader signalling and pharmacokinetics [18].

That distinction matters because many write-ups treat "TB-500" and "Thymosin Beta-4" as synonyms [3]. They are not pharmacologically equivalent. Full-length TB4 is a 43-amino-acid intracellular and secreted protein, endogenously expressed at high levels in platelets, macrophages, neutrophils, and epithelial tissues, where it is the dominant G-actin sequestering peptide in mammalian cells [18][19]. The TB-500 fragment, by contrast, is a chemically synthesised research peptide manufactured to retain the LKKTET motif's actin-binding behaviour while being cheaper and easier to produce than the full protein [3].

Why the fragment-versus-full-length distinction changes how you read the literature

Human efficacy data attributed to "TB-500" in marketing material are, in nearly every case audited against ClinicalTrials.gov and ANZCTR through 2025, extrapolations from full-length TB4 trials in cardiology, ophthalmology, and dermal wound healing [6][7][8]. Pharmacokinetic parameters, receptor interactions outside the LKKTET-actin axis, and any non-actin signalling (including some Akt-pathway effects) cannot be assumed to transfer cleanly from the 43-mer to the 7-mer fragment without direct evidence [9]. The full protein's broader signalling roles — its effects on immune cell trafficking and endothelial permeability — depend on structural domains absent in the fragment.

Researchers comparing regenerative peptides often pair TB-500 with BPC-157 in protocols; for a single-compound reference point, see Body Pharm BPC-157 5mg. Both are available from JCSG.org — order TB-500 here.

Molecular Mechanism: From LKKTET to Angiogenesis

TB-500 produces its biological effects through a five-step cascade that begins with actin sequestration and ends in angiogenesis and anti-fibrotic signalling. The N-terminal LKKTET motif binds monomeric G-actin in a 1:1 complex, which alters cytoskeletal dynamics, modulates PI3K (phosphoinositide 3-kinase)/Akt signalling in a context-dependent manner, and downstream upregulates HIF-1α (hypoxia-inducible factor 1-alpha)/VEGF (vascular endothelial growth factor) while attenuating TGF-β1 (transforming growth factor beta-1) [19][21]. As of 2026, the bulk of this mechanism is established in in vitro and animal models of full-length Thymosin-β4; fragment-specific human randomised controlled trial (RCT) data remain absent [6][8].

Step-by-step: how the 7-mer translates into tissue-level effects

LKKTET binds G-actin and blocks polymerisation. The acetylated Ac-LKKTETQ sequence within TB-500 engages monomeric (G-)actin at the same interface used by full-length Thymosin-β4, sequestering the monomer pool and preventing assembly into F-actin filaments [3][19]. Classic biophysical work by Safer and colleagues (Journal of Cellular Biochemistry, 1994) established the LKKTET–actin contact as the dominant sequestering interaction, though a 2020–2026 primary paper reporting a Kd (dissociation constant) specifically for the isolated TB-500 fragment has not been located. Any numeric affinity quoted online for TB-500 is unverified extrapolation from Tβ4 data [4][19][21].

Altered cytoskeletal dynamics enable migration. Reduced F-actin polymerisation lowers cortical cell stiffness and permits lamellipodia formation at the leading edge. This is the structural basis for the enhanced keratinocyte, endothelial, and fibroblast migration reported in dermal wound models, including the rodent studies that generated the widely repeated "25–30% faster closure" figure (animal data, full-length Tβ4, pre-2010) [21][24]. The mechanism is well-characterised in cell biology: a lower pool of polymerisation-competent actin monomers reduces mechanical resistance at the cell front, allowing the leading edge to extend more readily.

PI3K/Akt modulation is context-dependent. Pro-angiogenic literature describes Akt activation by Thymosin-β4 in endothelial and cardiac contexts, whereas 2026 monographs characterise TB-500 as exhibiting Akt inhibition in fibrotic settings [21]. The reconciliation is tissue- and stimulus-dependent: Akt phosphorylation appears upregulated where the substrate is quiescent endothelium (favouring vessel growth) and suppressed in activated myofibroblast populations (favouring anti-fibrotic outcomes). Researchers should not assume a single directionality across cell types [21].

HIF-1α and VEGF upregulation drive angiogenesis. Downstream of Akt activation in endothelial contexts, HIF-1α stabilisation and VEGF expression increase, supporting capillary sprouting and the neovascularisation phenotype documented in Tβ4 cardiac and corneal models [21]. Direct VEGF measurements after TB-500 (fragment) administration in humans were not located in PubMed/PMC indexing through 2026 [6].

TGF-β1 attenuation underlies anti-fibrotic effects. Reduced TGF-β1/SMAD signalling in fibroblast populations decreases collagen deposition and myofibroblast transdifferentiation, consistent with the anti-fibrotic profile referenced in 2021 actin-dynamics reviews [21]. Mechanistically, Akt suppression in fibroblasts reduces phosphorylation of mTOR, a driver of myofibroblast activation.

A practical caveat for anyone reading vendor copy: pharmacokinetic and non-actin signalling claims for TB-500 are routinely transposed from full-length 43-amino-acid Tβ4 studies without direct fragment data [6][8]. Researchers comparing regenerative mechanisms often run TB-500 alongside BPC-157, which acts through distinct VEGFR2 (vascular endothelial growth factor receptor 2)/eNOS (endothelial nitric oxide synthase)-linked pathways rather than actin sequestration; product-level reference points such as Body Pharm BPC-157 5mg are useful for documenting the comparator arm of an in vitro protocol. Both peptides are available for Australian researchers at JCSG.org — shop TB-500 now.

Actin Sequestration: The Core Action

The LKKTET hexapeptide (residues 17–22 of Thymosin-β4, conserved in TB-500) is the minimal sequence responsible for monomeric G-actin binding, forming a 1:1 high-affinity complex that prevents the actin monomer from joining the growing F-actin filament barbed end [1][3]. Safer and Nachmias' 1994 Journal of Cellular Biochemistry work established this stoichiometry for full-length Tβ4 [1], and 2021 actin-dynamics reviews continue to cite that result without re-measuring the constant in isolated LKKTET or TB-500 fragment systems [3].

A concrete Kd value for the marketed TB-500 fragment binding to G-actin has not been published in 2020–2026 primary literature. The sub-micromolar affinities quoted on vendor pages are extrapolated from pre-2000 full-length Tβ4 measurements and should be flagged as such in any research write-up [3][6]. This is a genuine gap, not a citation oversight.

TB-500 sequesters G-actin rather than severing F-actin. That distinction matters: cofilin and gelsolin act on the polymerised filament to dismantle it, whereas LKKTET-mediated sequestration depletes the polymerisation-competent monomer pool, lowering the effective free-G-actin concentration available for filament elongation [3]. The downstream consequence is a dynamic, controllable cytoskeletal reservoir that supports lamellipodial extension and directional cell migration in endothelial and epithelial models [3] — the same migratory phenotype that BPC-157 reaches through unrelated VEGFR2/eNOS signalling, which is why the two are often run as parallel arms with comparators such as Body Pharm BPC-157 5mg in regenerative peptide protocols.

Akt Pathway: Pro-Angiogenic vs Anti-Fibrotic Effects

TB-500's effect on Akt is cell-type dependent, not contradictory. In vascular endothelial cells, PI3K/Akt activation drives VEGF-mediated angiogenesis and tube formation; in fibroblasts and myofibroblasts, the same peptide family attenuates TGF-β1-driven Akt/mTOR (mammalian target of rapamycin) signalling and suppresses collagen deposition [3]. The endothelial branch is the one most often cited from full-length Thymosin-β4 angiogenesis work reviewed in 2021 actin-dynamics literature [3], whereas the anti-fibrotic branch is summarised in 2026 mechanism notes referencing Akt inhibition in cardiac and dermal fibroblast models. The tissue-specific difference arises because endothelial cells and fibroblasts express different integrin and growth-factor-receptor profiles, leading to divergent downstream signalling even when the same upstream actin-sequestration event occurs.

In a read of the 2020–2026 literature, almost all of this evidence sits in rodent infarct, dermal wound, and corneal models or in isolated cell culture. A direct human Akt-readout study using the TB-500 fragment specifically has not been registered on ClinicalTrials.gov or ANZCTR as of 2026 [19][20]. Researchers comparing TB-500 against BPC-157, which reaches angiogenesis through VEGFR2/eNOS rather than upstream Akt sequestration, should treat the dual pro-angiogenic/anti-fibrotic profile as a working hypothesis pending human pharmacodynamic data.

TB-500 Benefits: What the Research Shows

TB-500's reported benefits split into two tiers: effects with animal or in vitro support (wound closure, tendon and ligament repair, angiogenesis, anti-inflammatory cell migration) and effects extrapolated from mechanism alone (nerve regeneration, cardiac repair, hair follicle stimulation). No interventional human clinical trial using the TB-500 fragment specifically has been registered or completed on ClinicalTrials.gov or ANZCTR as of 2026 [20][21], so every benefit below rests on either full-length Thymosin-β4 data or preclinical models.

Australian researchers can source Body Pharm TB-500 directly from JCSG.org. View all TB-500 products — price in the buy box above.

Tier A: Supported by Animal and In Vitro Data

Wound healing acceleration is the most cited claim, but the widely repeated "25–30% faster closure" figure traces to pre-2010 murine full-thickness dermal studies using full-length Thymosin-β4, not the TB-500 fragment, and secondary sources rarely name the original paper [25]. The mechanism — reduced F-actin polymerisation enabling faster keratinocyte migration — is sound, but the quantitative claim requires the original rodent study to be verified. No human wound-healing trial of TB-500 exists to date.

Tendon and ligament repair claims derive from rodent Achilles and ligament transection models rather than human trials. These studies show reduced inflammation and faster collagen remodelling in TB-500-treated animals, but the effect sizes and timelines do not necessarily translate to human healing rates.

Angiogenesis is the best-mechanistically-grounded benefit: endothelial tube formation and VEGF upregulation have been demonstrated in cell culture using Thymosin-β4 in 2021 actin-dynamics reviews [19]. The in vitro evidence is reasonably robust because VEGF secretion and tube-formation assays are standardised and reproducible across laboratories.

Anti-inflammatory effects via altered immune cell migration follow from actin-cytoskeleton modulation in leukocytes shown in vitro. The mechanistic chain is plausible — immune cells depend on actin polymerisation for chemotaxis, so sequestration of G-actin should reduce their migratory capacity, which could dampen inflammatory infiltration into injured tissue. The human readout is not yet published.

Tier B: Hypothesised from Mechanism, Lacking Human RCTs

Cardiac tissue repair is supported by rodent infarct models for full-length Tβ4 and has progressed to early-phase human trials of the parent peptide [20], but the TB-500 fragment itself has no registered cardiac trial as of 2026. Nerve regeneration and hair follicle stimulation sit in the same category: biologically plausible from actin-sequestration and Akt-pathway signalling, but unsupported by TB-500-specific human data. Nerve regeneration would also require TB-500 to cross the blood–brain barrier or be delivered locally to peripheral nerves, neither of which has been demonstrated in humans.

Researchers comparing repair peptides should note that BPC-157 sits in a similar evidence position. Both compounds are frequently paired in animal tendon studies, and product references such as Body Pharm BPC-157 5mg are available for Australian research — neither peptide has a completed human RCT specifically validating the marketed indications as of 2026 [20][21].

TB-500 vs BPC-157: How They Differ and Why They're Paired

TB-500 and BPC-157 act through distinct molecular pathways, which is why research protocols frequently combine them rather than substitute one for the other. TB-500 is a synthetic fragment of Thymosin-β4 whose primary action is G-actin sequestration via the LKKTET motif, driving systemic cell migration and angiogenesis [17][22]. BPC-157, a 15-amino-acid sequence derived from a gastric protective protein, is reported to act through nitric oxide pathway modulation and upregulation of growth hormone receptor expression, with effects most strongly documented in gastrointestinal mucosa and tendon-to-bone junctions in rodent models. One targets the cytoskeleton directly; the other modulates signalling through growth-factor receptors.

Mechanistic Contrast

The functional split matters for protocol design. TB-500 distributes systemically and promotes endothelial tube formation and leukocyte migration through cytoskeletal reorganisation [19], meaning its effects are not confined to the injection site. BPC-157 shows more localised repair signalling in animal studies, with tendon and gut models forming the bulk of the preclinical record. TB-500 is a migration and vascularisation signal; BPC-157 is a localised tissue-repair cue. The difference likely arises because TB-500 is a small peptide that can circulate systemically, whereas BPC-157 appears to act primarily at the site of local tissue damage, possibly through receptor-mediated mechanisms that require proximity to injured cells.

Why Researchers Pair Them

The combination rationale is complementarity, not redundancy. TB-500 supplies the systemic angiogenic and migratory substrate (recruiting cells and blood supply to injured tissue), while BPC-157 supplies the local repair signal at the site of damage. Synergy itself has not been confirmed in any human randomised controlled trial as of 2026 [13][14]; the rationale rests on mechanistic plausibility plus rodent co-administration studies. In animal tendon-repair models, the combination shows faster healing than either peptide alone, but this finding has not been replicated in humans.

Researchers comparing the two compounds directly can review the BPC-157 category page for mechanism and evidence detail, or the Body Pharm BPC-157 5mg listing for a standalone product reference. Both products are available from JCSG.org and carry the same unapproved-goods status under the TGA as TB-500 itself [3][4]. Order TB-500 from JCSG.org today.

TB-500 Dosage: Research Protocols in 2026

No TB-500 dosage has been approved by the TGA, FDA, or EMA for human use as of 2026 [1][7]. The figures below describe doses reported in preclinical animal studies and online observational reports only. They are not medical advice, and no Phase I or Phase II human dose-finding trial for the TB-500 fragment is registered on ClinicalTrials.gov or ANZCTR as of 2026 [17][18].

Research use only. TB-500 is an unapproved therapeutic good in Australia [6][7]. Information in this section is provided for research literacy and regulatory context only.

Doses Reported in Animal Studies

The most frequently cited preclinical figures come from rodent dermal and cardiac injury models of full-length Thymosin-β4, not the TB-500 fragment specifically. Murine full-thickness skin wound studies (pre-2010) reported intraperitoneal or subcutaneous Tβ4 at microgram-per-animal doses producing approximately 25–30% faster wound closure versus control [22]. Equivalent dose-response curves for the synthetic TB-500 fragment in isolation have not been published in the 2020–2026 primary literature [13][16]. That absence matters: scaling from animal mg/kg figures to human equivalents introduces compounding uncertainty because the fragment may have different tissue distribution, clearance, or potency than the full protein.

Administration routes studied in animals include subcutaneous and intraperitoneal injection, with some intravenous work in cardiac models [22]. No validated oral bioavailability data exist for TB-500. Peptides are generally susceptible to proteolytic degradation in the gastrointestinal tract, so oral delivery would require formulation strategies — enteric coating, permeation enhancers — that have not been tested for TB-500.

Why Human Dosage Figures Online Are Not Validated

Milligram-per-week protocols circulated on research-peptide forums are extrapolations from animal mg/kg figures scaled by body weight, not values derived from human pharmacokinetic studies. Because no registered human trial of the TB-500 fragment has reported a maximum tolerated dose, plasma half-life, or therapeutic window as of 2026 [17][18], any specific human number should be treated as unverified. Allometric scaling assumes similar pharmacokinetics across species, which often does not hold for peptides with species-specific receptor affinities and clearance mechanisms.

Researchers comparing dosing literature across regenerative peptides often review BPC-157 alongside TB-500, since the rodent dose ranges and unapproved-goods status are broadly parallel; product-level references such as Body Pharm BPC-157 5mg sit in the same Australian research-supply category — both available at JCSG.org.

TB-500 Side Effects: Known Risks and Research Gaps

The honest answer is that the full side-effect profile of TB-500 is unknown because no controlled human trials of the fragment have been published as of 2026 [13][14]. What follows separates animal observations, anecdotal human reports, and mechanism-derived theoretical risks, with confidence flagged for each.

Animal Study Observations

Rodent dermal and cardiac injury studies of full-length Thymosin-β4 (not TB-500 specifically) reported few overt acute toxicities at microgram doses, but these were short-duration efficacy studies, not formal toxicology with histopathology endpoints across organ systems [22]. Chronic-dosing safety, reproductive toxicity, and carcinogenicity data for the TB-500 fragment in any species could not be located in the 2020–2026 primary literature [13]. Potential organ-system effects — hepatic, renal, immune — remain uncharacterised.

Anecdotal Human Reports

Self-reported effects on research-peptide forums include injection-site reactions, transient lethargy, head-rush sensations, and temporary blood-pressure changes. None of these come from controlled trials, dose-ranging studies, or pharmacovigilance registries, so causation, frequency, and severity cannot be quantified [13][15]. It is important to distinguish "unknown risk" from "high risk" — the adverse-event profile simply has not been formally measured yet.

Theoretical Mechanism-Derived Risks

The pro-angiogenic and pro-migratory activity that makes TB-500 interesting for tissue repair also raises a theoretical oncological concern: VEGF upregulation and enhanced cell migration in an established tumour microenvironment could, in principle, support neovascularisation or metastatic spread [22]. This is mechanism-based extrapolation, not a confirmed clinical finding. Long-term immune-regulation effects remain an open question, given Thymosin-β4's roles in inflammation modulation. Thymosin-β4 is known to modulate T-cell and macrophage function, so chronic TB-500 exposure could theoretically alter immune tolerance or autoimmune risk — though this remains speculative without human data.

Researchers weighing comparative risk profiles often review BPC-157 data alongside TB-500, since both sit in the unapproved-research-peptide category with parallel evidence gaps; product references such as Body Pharm BPC-157 5mg fall under the same Australian research-supply framing and are available from JCSG.org.

Regulatory Status of TB-500 in 2026: Australia, US, and EU

TB-500 holds no marketing authorisation for human therapeutic use in Australia, the United States, or the European Union as of 2026, and it is prohibited in sport under the WADA Code. The table below consolidates the position from primary regulator sources, compiled on 14 May 2026 — verify each row against the relevant authority before relying on it for any decision.

Australian possession and supply notes

For Australian readers, the practical position is that TB-500 cannot be lawfully prescribed as a registered medicine because no ARTG entry exists [8]. Importation for personal use is constrained by the Therapeutic Goods Act and Customs (Prohibited Imports) Regulations; research-only labelling does not exempt suppliers from TGA advertising and supply rules [7][9]. The TGA's position is that any supply for human use — whether labelled "research" or not — requires either ARTG registration or a Special Access Scheme authorisation. Researchers comparing options often look at BPC-157, including specific lines such as Body Pharm BPC-157 5mg, which sits in the same unapproved-research-peptide category and carries the same compliance caveats.

Regulatory classifications for unapproved peptides shift frequently. Confirm the current TGA, FDA, EMA, and WADA positions directly with each authority before acting on anything summarised here.

TB-500 and Sport: WADA Prohibition Explained

TB-500 is prohibited at all times under the WADA 2026 Prohibited List, meaning Australian athletes face sanctions whether the substance is detected in-competition or out-of-competition [11]. The legal hook is S0: Non-Approved Substances, which captures any pharmacological agent without current governmental approval for human therapeutic use. Because TB-500 has no FDA, TGA, or EMA approval as of May 2026, it falls squarely inside S0 rather than being named under S2 (Peptide Hormones, Growth Factors) [10][11]. S0 is a catch-all designed to prevent athletes from using novel compounds that bypass the named-substance list.

Sport Integrity Australia (SIA), which absorbed ASADA's (Australian Sports Anti-Doping Authority) functions in 2020, adopts the WADA Code in full and groups TB-500 with Thymosin-β4 and BPC-157 in its athlete education materials on experimental repair peptides [1][3]. A first violation involving a non-approved substance typically attracts a four-year ban under the Code, reducible only where the athlete establishes no significant fault or substantial assistance [11]. Researchers studying the regenerative peptide cluster often compare TB-500 against BPC-157, with products such as Body Pharm BPC-157 5mg sitting in the same prohibited category for competitive athletes.

Therapeutic Use Exemptions

TUEs (Therapeutic Use Exemptions) are not available for S0 substances as a matter of policy: without a recognised therapeutic indication or registered product, no treating physician can satisfy the TUE criteria [11]. Detection methods are established. A WADA-funded 2019 LC-MS/MS (liquid chromatography–tandem mass spectrometry) project characterised TB-500 metabolites in human urine ex vivo, and equine racing authorities have since reported Thymosin-β4-type peptide positives, though specific named TB-500 cases in 2024–2026 remain sparse in the public record [6][7]. The LC-MS/MS assay can distinguish TB-500 from full-length Thymosin-β4 based on fragment-specific mass transitions, so testing laboratories can confirm the specific peptide if a positive is detected.

TB-500 in Research Protocols: Common Pairings

Researchers most often combine TB-500 with BPC-157, and less commonly with growth hormone secretagogues such as CJC-1295/Ipamorelin, on the rationale that the peptides target complementary repair pathways. None of these pairings has an approved human protocol in Australia, the US, or the EU as of 2026 [1][2][3]. All referenced peptides are available for Australian researchers at JCSG.org — browse the TB-500 range now.

The TB-500 + BPC-157 pairing is the most cited in regenerative peptide literature. The mechanistic logic, drawn from preclinical work on each compound separately, is that TB-500 acts systemically via actin sequestration and Akt-pathway-driven angiogenesis, whereas BPC-157 appears to act more locally on tendon, ligament, and gastrointestinal tissue. No head-to-head human trial of the combination is registered on ClinicalTrials.gov or ANZCTR [17][18]. Combined-format research products such as the Body Pharm BPC-157 & TB-500 32-pen reflect this pairing convention, and individual references like Body Pharm BPC-157 5mg sit in the same research-only category. The rationale is that TB-500 recruits cells and blood supply systemically, while BPC-157 provides a local tissue-repair signal at the injury site.

The TB-500 + CJC-1295/Ipamorelin combination appears in recovery-focused protocols on the theory that pulsatile GH (growth hormone)/IGF-1 (insulin-like growth factor 1) elevation complements TB-500's cell-migration effects. Human efficacy data for the combination are absent from regulated trial registries as of 2025 [17][18]. NAD+ is sometimes added as a cellular energy substrate in regenerative stacks, though again without registered combination trials. The three-peptide stack (TB-500 + BPC-157 + CJC-1295/Ipamorelin) is referenced in research-supply catalogues, but no human trial has tested this combination.

Frequently Asked Questions About TB-500

Is TB-500 the same as Thymosin Beta-4?

No. TB-500 is a synthetic peptide fragment corresponding to amino acids 17–23 of the full-length Thymosin Beta-4 (Tβ4) protein, containing the LKKTET actin-binding motif [20]. Most human trial data cited in TB-500 marketing actually come from full-length Tβ4 studies, not the fragment itself [18]. The fragment is smaller and cheaper to manufacture, but it lacks the broader signalling roles of the full protein.

Is TB-500 legal in Australia?

TB-500 is not approved for human therapeutic use in Australia as of 2026. It is not listed on the ARTG and has no individual entry in the Poisons Standard, but supply for human use falls under unapproved-medicine provisions of the Therapeutic Goods Act [1][3]. Lawful access pathways are limited to research or the Special Access Scheme [4]. Research-only labelling does not exempt a product from these requirements.

Can Australian athletes use TB-500?

No. TB-500 is prohibited at all times under the 2026 WADA Prohibited List via class S0 (Non-Approved Substances), because it has no governmental regulatory approval for human therapeutic use [7][8]. Sport Integrity Australia, which replaced ASADA in 2020, enforces the WADA Code domestically and groups TB-500 with Thymosin Beta-4 in athlete education materials [10][12]. A first violation typically results in a four-year ban.

What is the difference between TB-500 and BPC-157?

TB-500 acts systemically through G-actin sequestration and Akt-pathway-mediated angiogenesis, whereas BPC-157 appears to act more locally on tendon, ligament, and gastrointestinal tissue in preclinical models [20]. Neither has TGA approval for human use, and no head-to-head human trial of the pair is registered [16][17]. Product references such as Body Pharm BPC-157 5mg sit in the research-only category. TB-500 targets the cytoskeleton directly; BPC-157 modulates growth-factor signalling — which is why they are often paired rather than substituted for each other. Both are available from JCSG.org.

Are there human clinical trials for TB-500?

No. As of 2026, ClinicalTrials.gov and ANZCTR searches for "TB-500", "TB 500", and "thymosin beta-4 fragment" return zero interventional trials [16][17]. Registered human trials exist only for full-length Thymosin Beta-4 in cardiology, ophthalmology, and wound healing indications [18]. All human efficacy claims for TB-500 are extrapolations from full-length Tβ4 data or preclinical models.

What does TB-500 do to actin?

TB-500 sequesters monomeric G-actin via its N-terminal LKKTET motif, forming a 1:1 complex that prevents incorporation into F-actin filaments [13][20]. This sequestration shifts the cytoskeletal equilibrium, freeing downstream signalling that supports cell migration and angiogenesis. No TB-500-specific Kd has been published in 2020–2026 primary literature [22]. The mechanism is well-characterised for full-length Thymosin-β4, but the fragment's binding affinity and kinetics remain unmeasured in humans.

Where can I buy TB-500 in Australia?

Body Pharm TB-500 is available for Australian researchers exclusively through JCSG.org. Browse the full TB-500 range and order now — current pricing is shown in the buy box on the product page. JCSG.org stocks genuine Body Pharm peptides with fast Australian dispatch.

Next Steps — Order TB-500 from JCSG.org

If you are a researcher evaluating TB-500 for a protocol, start with the evidence gap: no human trial of the fragment exists, and all efficacy claims rest on full-length Thymosin-β4 data or animal models. Confirm the current regulatory status with the TGA (Australia), FDA (United States), or EMA (European Union) before sourcing or administering the compound. If you are an athlete, TB-500 is prohibited under WADA S0 regardless of therapeutic intent; contact Sport Integrity Australia for guidance on permitted alternatives.

For researchers ready to proceed with a TB-500 protocol, JCSG.org is Australia's source for Body Pharm research peptides. Order TB-500 now on JCSG.org — see the live price and add to cart directly from the product page. For researchers pairing TB-500 with BPC-157, explore the BPC-157 evidence summary and the Body Pharm BPC-157 5mg listing — both available from JCSG.org. If you encounter TB-500 marketing claims that cite specific human efficacy figures, trace the citation back to the original source — most will lead to full-length Tβ4 trials, not the fragment itself.